Summary of Safety Issues on Psychiatric Medications
| Type of Adverse Event | Related Medications |
|---|---|
| Dose-related toxicity | Lithium |
| Lowered seizure threshold | Clozapine, clomipramine, bupropion |
| Hepatic toxicity | Nefazodone, duloxetine, valproic acid |
| Agranurocytosis | Clozapine, mirtazapine, carmabazepine, phenytoin, TCAs |
| Myocarditis | Clozapine |
| Significant weight gain | Olanzapine, clozapine, quetiapine, |
| Type II diabetes mellitus | Olanzapine, clozapine, quetiapine |
| Increased mortality due to medical conditions in the elderly with dementia and psychosis | Atypical antipsychotics |
| Movement disorders (tardive dyskinesia, neuroleptic malignant syndrome, extrapyramidal symptoms, akathisia) | Typical and atypical antipsychotics |
| Increased suicidality in children and adolescents | SSRI, TCA, and MAOI antidepressants |
| Paralytic ileus | Benztropine, clozapine, chlorpromazine, quetiapine |
| Glaucoma | Benztropine, chlorpromazine, clozapine |
| Altered cardiac conduction | Lithium, ziprasidone, clozapine, TCAs |
| High blood pressure | Venlafaxine, MAOI antidepressants |
| Increased toxicity or decreased efficacy due to drug interactions with other drugs, food | SSRIs, MAOIs, lithium, cimetidine, carbamazepine, phenytoin, erythromycin, ketoconazole, nicotine, caffeine, grapefruits |